UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 180 filers reported holding UNIQURE NV in Q2 2023. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,223,870 | -41.4% | 182,395 | 0.0% | 0.00% | -50.0% |
Q2 2023 | $2,090,247 | -40.0% | 182,395 | +5.5% | 0.00% | -33.3% |
Q1 2023 | $3,481,400 | +51.9% | 172,860 | +71.0% | 0.01% | +50.0% |
Q4 2022 | $2,291,846 | +18.1% | 101,096 | -2.3% | 0.00% | 0.0% |
Q3 2022 | $1,941,000 | +646.5% | 103,488 | +642.4% | 0.00% | – |
Q2 2022 | $260,000 | -91.2% | 13,940 | -78.6% | 0.00% | -100.0% |
Q2 2020 | $2,939,000 | -12.6% | 65,210 | -8.0% | 0.00% | -40.0% |
Q1 2020 | $3,362,000 | -28.7% | 70,864 | +7.6% | 0.01% | +25.0% |
Q4 2019 | $4,718,000 | +116.8% | 65,829 | +19.1% | 0.00% | +100.0% |
Q3 2019 | $2,176,000 | -63.6% | 55,254 | -27.8% | 0.00% | -66.7% |
Q2 2019 | $5,982,000 | +27.0% | 76,548 | -3.0% | 0.01% | +20.0% |
Q1 2019 | $4,709,000 | +214.4% | 78,945 | +51.9% | 0.01% | +150.0% |
Q4 2018 | $1,498,000 | -24.2% | 51,986 | -4.3% | 0.00% | 0.0% |
Q3 2018 | $1,977,000 | +5.3% | 54,332 | +9.4% | 0.00% | 0.0% |
Q2 2018 | $1,877,000 | – | 49,653 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |